Aloeride As a Potential Treatment For Gastrointestinal Inflammatory
Diseases

Aloeride has been found to effectively prevent and treat certain
autoimmune diseases such as rheumatoid arthritis and ulcerative
colitis. It has been shown aloe kills bacterium, which causes chronic
duodenal and gastric ulcers caused by a bacterial infection. It has
also been shown to reduce acid secretion.

Drugs were discovered to reduce acid secretion, but people with ulcers
did not seem to heal or their improvement would only be temporary.
Then they would relapse and have more serious episodes of ulceration
with all the painful symptoms. Chronic gastritis and stomach ulcers
can lead to a tendency to cancer of the stomach, just as ulcerative
colitis can lead to colon cancer.

When looking into the studies of aloe you will find it decreases
stomach acid production, which will protect the lining of the stomach
from ulcers and it kills the bacteria, which has a tendency to lead to
chronic stomach irritation.

The following is a study on the effects of aloe vera on patients with
inflammatory bowel disease while under therapeutic evaluation for
their condition. The Aim is to assess the effects of aloe vera in
vitro on the production of reactive oxygen metabolites, eiosanoids,
and interleukin-8, which could be pathogens in inflammatory bowel
disease. The Results were aloe vera gel had an inhibitory effect on
reactive oxygen metabolite production; 50% inhibition at 1 in 1000
dilution and at 1 in 10-50 dilution with biopsies. Aloe vera inhibited
the production of prostaglandin E2 by 30% at 1 in 50 dilution, but had
no effect on thromboxane B2 production. The release of the
interleukin-8 cells dropped by 20% with the aloe vera diluted at 1 in
100, but not a 1 in 10 or 1 in 1000 dilutions. The Conclusion of it
all is the anti-inflammatory actions of aloe vera gel in vitro provide
back up for the proposal aloe vera may have a therapeutic effect in
inflammatory bowel disease.

Another study performed on aloe vera to study it effectiveness with
inflammatory bowel disease. The Aim of this study is to perform a
double blind, randomized, placebo-controlled trial of the efficiency
and safety of aloe vera gel for the treatment of mildly to moderate
active ulcerative colitis. The Method will be to use forty-four
hospital outpatients who could be evaluated were randomly given oral
aloe gel or a placebo at 100 ml twice a day for 4 weeks, in a 2: 1
ratio. The primary outcome was clinical remission, sigmoidoscopic
remission, and histological remission. The secondary outcome measures
included changes in the Simple Clinical Colitis Activity Index, Baron
score, histology score, hemoglobin, platelet count, erythrocyte
sedimentation rate, C-reactive protein and albumin. The Results were
clinical remission, improvement and responses in nine, about 30%, 11,
about 37%, and 14, about 47% of the 30 patients who received the aloe
vera gel compared with one, 7% and two, 14% of 14 patients taking
placebo. The Simple Clinical Colitis Activity Index and histological
scores decreased noticeably during treatment with aloe vera, compared
to no decreases with the placebo. The Conclusion is aloe vera taken
orally for 4 weeks produced a clinical response more often than
placebo; it also reduced the histological disease activity and
appeared to be safe. Additional evaluation of the potential of aloe
vera gel is needed in inflammatory bowel disease.

Read Articles: http://www.affiliates.halloasia.com

Visit WebSite: http://track.moreniche.com/hit.php?w=123912&s=75